Retension Pharmaceuticals Inc.

Retension Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing medicines for the treatment of hypertension and other cardiovascular diseases. Its product, RTN-001, is a next-generation, once-daily, oral, small molecule phosphodiesterase-5 inhibitor designed to reduce blood pressure by potentiating nitric oxide signaling, a key mechanism underlying the development and severity of hypertension. The company was founded by Eric Keller and Paul Sweetnam in 2023 and is headquartered in Falls Church, VA.

業界

Medical - Pharmaceuticals

セクター

Healthcare

本社

US

最高経営責任者（CEO）

Eric L. Keller

上場以来

2026年10月9日

従業員

12